Herantis Pharma Oyj
The answer first
Does Herantis Pharma beat the market?
No, Herantis Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 0% of Nordic stocks
- Quality1
- Value5
- Trend16
No. 194 of 195 in healthcare
Max for seven days
Follow Herantis Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Herantis Pharma
Your first answer is free, no account needed.
Do you own Herantis Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Herantis Pharma and a few more. Free, no card.
Super Stock+45.9%In short
- Herantis Pharma has fallen 31.4% over the past year, including dividends.
- Overall, Herantis Pharma ranks better than 0% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 73.6%. The price is 86.6% below its peak now.
What do analysts think of Herantis Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 0% of Nordic stocks.
No. 194 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 196 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity−4.33
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−392.4%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 163 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equitynegative earnings
- P/SPrice divided by sales288.3
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 138 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−11.8%
- 6 months−23.7%
- 9 months−35.5%
- 12 months−31.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Herantis Pharma
Herantis Pharma Oyj is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 14 employees.
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. Herantis Pharma Oyj was incorporated in 2008 and is based in Espoo, Finland.


See the full analysis of Herantis Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card